Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China

Table 6 Treatment response comparisons (n = 3563)

	PPI vs MPA		PPI vs MPA + PPI		PPI vs MPA + PPI + PD
	OR (95%WCL)	P value	OR (95%WCL)	P value	OR (95%WCL)	P value
Epigastric pain	0.73 (0.54-0.98)	0.039	0.46 (0.36-0.59)	< 0.001	0.42 (0.30-0.58)	< 0.001
Abdominal distension	0.81 (0.60-1.09)	0.162	0.81 (0.63-1.04)	0.091	0.53 (0.38-0.73)	< 0.001
Postprandial fullness	0.51 (0.38-0.69)	< 0.001	0.71 (0.55-0.93)	0.011	0.45 (0.33-0.62)	< 0.001
Early satiety	0.38 (0.27-0.54)	< 0.001	0.59 (0.43-0.80)	< 0.001	0.42 (0.29-0.61)	< 0.001
Acid regurgitation	0.68 (0.50-0.93)	0.016	0.65 (0.50-0.85)	0.001	0.38 (0.28-0.53)	< 0.001
Nausea	0.44 (0.31-0.63)	< 0.001	0.77 (0.57-1.06)	0.106	0.57 (0.39-0.83)	0.004
Belch	0.50 (0.37-0.69)	< 0.001	0.81 (0.61-1.07)	0.133	0.36 (0.26-0.51)	< 0.001
Vomiting	0.47 (0.31-0.71)	< 0.001	0.94 (0.64-1.37)	0.730	0.79 (0.49-1.26)	0.322
Others	0.21 (0.11-0.37)	< 0.001	1.19 (0.64-2.22)	0.578	0.61 (0.31-1.23)	0.168

MPA: Mucosal protective agent; PPI: Proton pump inhibitor; PD: Prokinetic drug; WCL: Weighted case load.